BMC ophthalmology · 2026
Association between capsulectomy shunt revision and Ahmed glaucoma valve implant exposure--Shanghai Ahmed glaucoma valve implant exposure (AGVIE) study.
Clinical StudyСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Feng, Jin Manman, Yu Xiaobo, Chen Junyi, Dai Yi, Chen Yuhong, Wang Jiajian, Chen Xueli, Wang Li, Fang Yuan, Wang Kaidi, Liu Tingting, Kwan Ye Lin, Qian Shaohong, Sun Xinghuai, Kong Xiangmei
Аннотация
BACKGROUND: The Ahmed Glaucoma Valve (AGV) is a drainage device commonly used in the treatment of refractory glaucoma. Implant exposure is a major cause of surgical failure. This study aimed to identify factors associated with AGV exposure.
METHODS: This retrospective cohort study included all inpatients who underwent primary AGV implantation at the Eye & ENT Hospital of Fudan University between January 2015 and December 2024. Baseline demographic and surgical data were collected. Factors associated with AGV exposure were evaluated using univariate and multivariate logistic regression.
RESULTS: In this comprehensive cohort study, involving a total of 2,905 eyes, with participants having a mean age of 49.2 ± 18.0 years and 64% being male, we observed that AGV exposure occurred in 75 eyes, accounting for an incidence rate of 2.6% (95% CI, 2.0-3.2%). Capsulectomy shunt revision (CSR) was associated with AGV exposure in both univariable analysis (OR 3.72, 95% CI 1.73-7.98; P < 0.001) and multivariable analysis (OR 3.95, 95% CI 1.79-8.69; P < 0.001).
CONCLUSIONS: The crude incidence of AGV exposure was 2.6%. CSR was statistically associated with AGV exposure, although this finding should be interpreted cautiously given the retrospective design and methodological limitations. Careful surgical planning and close postoperative monitoring may therefore be warranted.
CLINICAL TRIAL REGISTRATION: Not applicable.
METHODS: This retrospective cohort study included all inpatients who underwent primary AGV implantation at the Eye & ENT Hospital of Fudan University between January 2015 and December 2024. Baseline demographic and surgical data were collected. Factors associated with AGV exposure were evaluated using univariate and multivariate logistic regression.
RESULTS: In this comprehensive cohort study, involving a total of 2,905 eyes, with participants having a mean age of 49.2 ± 18.0 years and 64% being male, we observed that AGV exposure occurred in 75 eyes, accounting for an incidence rate of 2.6% (95% CI, 2.0-3.2%). Capsulectomy shunt revision (CSR) was associated with AGV exposure in both univariable analysis (OR 3.72, 95% CI 1.73-7.98; P < 0.001) and multivariable analysis (OR 3.95, 95% CI 1.79-8.69; P < 0.001).
CONCLUSIONS: The crude incidence of AGV exposure was 2.6%. CSR was statistically associated with AGV exposure, although this finding should be interpreted cautiously given the retrospective design and methodological limitations. Careful surgical planning and close postoperative monitoring may therefore be warranted.
CLINICAL TRIAL REGISTRATION: Not applicable.